Considering that placental gp96-pulsed BMDC immunization exhibited significantly stronger prophylactic and therapeutic efficacy compared to placental gp96 immunization alone (Figs 3 and 4), it’s plausible that the treatment of placental gp96 combined with BMDCs could bypass RAP-mediated CD91 blockage in the tumor microenvironment. This evidence concerns the gene HSP90B1 and neoplasm.